Gene Therapy Market to Grow at 25% CAGR, Hits $49.3 Billion by 2032

Introduction

The global gene therapy market size is expected to reach USD 49.3 billion by 2032, up from USD 5.6 billion in 2022, growing at a CAGR of 25% from 2022 to 2032. This rapid expansion is driven by several key factors. A major driver is the increasing prevalence of genetic disorders and chronic diseases, which create a strong demand for innovative treatments. Advances in gene editing technologies, such as CRISPR, and novel gene delivery methods have accelerated the development of effective gene therapies. The approval of multiple gene therapy products, including treatments for blood cancers and inherited retinal disorders, demonstrates their potential to address previously unmet medical needs.

Government support and regulatory frameworks are crucial for this growth. Comprehensive guidelines and expedited programs, such as the Regenerative Medicine Advanced Therapy (RMAT) designation, facilitate the development and approval of gene therapies. These frameworks ensure new treatments meet safety and efficacy standards while fostering innovation. Additionally, the FDA has provided guidance on manufacturing and clinical development challenges, offering clarity and support to product developers.

Public and private funding is also instrumental in advancing research and development. Initiatives like the Cell and Gene Therapy Access Model aim to improve access to transformative treatments for patients with severe and rare diseases. This model promotes outcomes-based agreements between states and manufacturers, making it easier to finance high-cost therapies and ensuring payments are tied to treatment success.

Strategic collaborations between companies and research institutions further enhance the market. These partnerships enable the sharing of expertise and resources, leading to the development of advanced gene therapies. Early regulatory advice programs help sponsors navigate preclinical requirements and streamline the development process, fostering innovation and accelerating the introduction of new treatments.

Recent developments in the gene therapy market showcase notable advancements by leading companies. In June 2021, Biogen Inc. announced positive results from their Phase 3 STAR study of timrepigene empacrvovec, an investigational gene therapy for choroideremia. This genetic disorder causes progressive vision loss, and the study’s success represents a significant step toward providing a potential treatment for this currently untreatable condition. Similarly, in February 2021, Spark Therapeutics began dosing participants in their international gene therapy clinical trial for Pompe disease, known as the RESOLUTE study. This trial investigates SPK-3006, a liver-directed adeno-associated viral (AAV) vector gene therapy. These advancements highlight the potential of gene therapies to address rare genetic disorders and enhance patients’ quality of life.

Key Takeaways

• Market Size: The global gene therapy market is expected to reach USD 49.3 billion by 2032, growing from USD 5.6 billion in 2022.
• Market Growth: The gene therapy market is projected to grow at a CAGR of 25% from 2022 to 2032.
• Type Analysis: The viral vector segment is expected to hold the largest revenue share, exceeding 85%, during the forecast period.
• Gene Type Analysis: The antigen segment has held the largest market share and is expected to maintain its lead during the forecast period.
• Delivery Methods Analysis: The in-vivo method segment held the largest market share during the forecast period. The increasing adoption of in-vivo therapies globally is anticipated to drive market growth in the future.
• Disease Indication Analysis: The oncology segment dominated the global gene therapy market in terms of revenue during the forecast period and is expected to sustain its dominance.
• Distribution Channel Analysis: The hospitals segment is anticipated to hold the highest market share throughout the forecast period, driven by the accessibility and availability of treatment methods in these facilities.

Gene Therapy Statistics

• FDA Approvals in 2022: 27 cell and gene therapies received approval.
• Clinical Trials in 2022: Over 1,500 clinical trials for these therapies were active, 90% in early stages.
• Investment Trends in 2022: Expected investments ranged from $9.8 billion to $13.5 billion.
• Venture Capital Funding in 2022: Funding reached 40% of the 2021 total in just the first half of the year.
• IND Applications in 2020: The FDA received more than 350 new investigational new drug applications.
• Clinical Holds from 2020 to 2022: A total of 33 clinical holds were placed.
• Active and Resolved Holds by End of 2022: 5 clinical holds remained active; 26 were resolved.
• Hold Duration: Average hold lasted 6.2 months, with a range of 2 to 19 months.
• FDA Review Time: The FDA typically responded to holds within 30 days and reviewed sponsor responses in the same timeframe.
• Protocol Amendments: 50% of resolved holds required protocol changes, taking an average of 4.8 months.
• CMC Data Requests: 25% of resolved holds involved amendments to Chemistry, Manufacturing, and Controls data, resolved within 8.4 months on average.
• Adverse Event Assessments: Resolutions related to adverse events took about 6.5 months for 25% of the cases.
• Preclinical Data Issues: These concerns accounted for 9% of holds, resolved within an average of 4 months.
• Product Types in Holds: Holds involved 27% CAR T cell therapies, 15% lentiviral-based, 45% AAV-based, and 13% other therapies.
• CAR T Cell Therapy Holds: Most were resolved within an average of 4.1 months, primarily due to safety issues.
• Patient Deaths and Holds: Three holds linked to patient deaths or adverse events were resolved within an average of 2.3 months.
• Corporate Implications: Three clinical holds had significant impacts on companies, affecting industry partnerships and sponsor support.
• FDA’s Prediction for 2025: The FDA anticipates approving 10-20 new therapies annually.
• New Approvals Expected in 2023: Up to 13 new therapies may receive approval in the US and Europe.
• EU Pharmaceutical Legislation Revision: Proposal expected in the first quarter of 2023.
• Asia-Pacific Growth: The number of developers in Asia-Pacific increased by 271% over five years.
• Growth in Trials: Gene therapy trials grew from 1,800 to over 5,000 over the last decade.
• Clinical Trials Overview: More than 2,000 trials are currently underway, with 200 in Phase III.
• FDA Modernization: The FDA’s Office of Tissues and Advanced Therapies transitioned to the “Office of Therapeutic Products”.
• EU Challenges: Seven of 23 advanced therapy medicinal products approved in the EU were withdrawn from the market.

Emerging Trends

• Increased FDA Approvals: The FDA’s proactive approach to gene therapy includes several initiatives designed to expedite the approval process for new therapies. The number of approved gene therapies has surged in recent years, driven by advances in clinical research and improved understanding of genetic disorders. Programs like Breakthrough Therapy Designation and Priority Review are crucial for accelerating the development of innovative treatments. Recent approvals, including therapies for inherited retinal diseases and rare genetic disorders, underscore the agency’s commitment to fostering progress in this field. As more gene therapies demonstrate their efficacy, the trend towards increased approvals is expected to continue, expanding the availability of cutting-edge treatments.
• Advancements in Gene Editing: Gene editing technologies such as CRISPR/Cas9 and TALENs have revolutionized the field of gene therapy by enabling precise modifications at the genetic level. These tools have made it possible to target specific genes for correction or deletion, offering potential cures for previously untreatable conditions. Innovations in gene delivery methods, including advanced nanoparticles and novel viral vectors, are enhancing the precision and efficiency of gene editing. Researchers are also exploring new editing technologies, such as base editors and epigenome editors, which promise even greater accuracy and fewer off-target effects, further advancing the potential of gene therapies.
• Focus on Rare Diseases: Gene therapy is increasingly focusing on rare and orphan diseases, which are often underserved by traditional treatments. The high cost of developing therapies for these conditions is mitigated by incentives such as orphan drug designations, which offer benefits like market exclusivity and financial grants. The focus on rare diseases is driven by the potential for gene therapies to provide transformative solutions where conventional treatments are lacking. Recent advancements include therapies for rare genetic disorders such as spinal muscular atrophy and bubble boy disease, highlighting the growing impact of gene therapy in these niche areas.
• In-Vivo Therapy Development: In-vivo gene therapy, where therapeutic genes are delivered directly into a patient’s cells within their body, is gaining significant attention. This approach is beneficial for targeting diseases within their natural tissue environment and avoiding the complexities associated with ex-vivo therapies, where cells are modified outside the body. Advances in vector design, such as improved adeno-associated viral vectors and new methods for targeted delivery, are enhancing the safety and effectiveness of in-vivo therapies. Ongoing research aims to overcome challenges related to immune responses and long-term gene expression, making in-vivo gene therapy a promising area for future development.
• Oncology Applications: Gene therapy is making substantial strides in oncology, with numerous clinical trials investigating novel treatments for various types of cancer. CAR T-cell therapy, which involves engineering a patient’s T cells to target cancer cells, has achieved remarkable results in treating hematological malignancies such as leukemia and lymphoma. Researchers are also exploring gene therapies for solid tumors, developing strategies to enhance the specificity and efficacy of these treatments. Innovations in gene editing and immune modulation are expected to drive further advancements, offering new therapeutic options for patients with cancer.
• Regulatory Frameworks and Guidance: Regulatory frameworks for gene therapy are evolving to support the rapid development of new treatments. The FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, along with similar programs in Europe and other regions, provides a structured pathway for expedited development and review. These frameworks are designed to address the unique challenges of gene therapy, including complex manufacturing processes and long-term safety monitoring. Recent updates to guidelines and the introduction of new regulatory initiatives are facilitating innovation while ensuring that new therapies meet high standards of safety and efficacy.
• Public and Private Funding: The gene therapy sector benefits from substantial funding from both public and private sources, driving research and development efforts. Government initiatives, such as the National Institutes of Health (NIH) funding programs and various research grants, provide essential support for early-stage research and clinical trials. Private investment from venture capitalists, biotechnology firms, and pharmaceutical companies complements this funding, accelerating the development of new therapies. Recent investments have focused on scaling up production capabilities, advancing clinical trials, and expanding the range of therapeutic applications.
• Strategic Collaborations: Strategic collaborations between biotechnology companies, academic institutions, and healthcare organizations are crucial for advancing gene therapy. These partnerships facilitate the sharing of expertise, resources, and technologies, leading to the development of innovative treatments. Collaborative efforts include joint ventures to scale up manufacturing, partnerships to navigate regulatory processes, and alliances for preclinical and clinical research. These collaborations are essential for overcoming the challenges associated with gene therapy and accelerating the translation of research into clinical practice.
• Rising Clinical Trials: The number of clinical trials in gene therapy is on the rise, reflecting the robust pipeline of new treatments under investigation. Clinical trials are essential for evaluating the safety and efficacy of gene therapies and for obtaining regulatory approval. The expanding range of trials includes studies focused on improving delivery methods, exploring new therapeutic targets, and evaluating the long-term effects of gene therapies. The growing number of trials is indicative of the dynamic nature of the gene therapy field and the ongoing efforts to develop new and effective treatments for a variety of conditions.

Use Cases

• Sickle Cell Disease: Gene therapies like Casgevy and Lyfgenia are at the forefront of addressing sickle cell disease, a condition characterized by abnormally shaped red blood cells that lead to painful vaso-occlusive crises and other severe complications. Utilizing CRISPR/Cas9 technology, these therapies aim to correct the genetic mutation responsible for the disease by editing the patient’s own hematopoietic stem cells. Lentiviral vectors are used to introduce functional copies of the beta-globin gene into these cells. The goal is to restore normal hemoglobin production, which can reduce the frequency and severity of pain episodes, improve blood flow, and enhance the patient’s overall quality of life. The potential for long-term relief and even a potential cure represents a significant advancement in the management of this debilitating condition.
• Duchenne Muscular Dystrophy (DMD): Elevidys targets Duchenne Muscular Dystrophy, a severe muscle-wasting disease caused by mutations in the dystrophin gene. The therapy involves delivering a micro-dystrophin gene, which encodes a shorter but functional version of the dystrophin protein. This gene is delivered via a viral vector to muscle cells, aiming to produce a functional dystrophin that helps maintain muscle integrity and function. By slowing down muscle degeneration, Elevidys has the potential to improve mobility, extend life expectancy, and significantly enhance the quality of life for patients. This therapy provides a new hope for managing DMD and represents a critical advancement beyond traditional supportive treatments and corticosteroids.
• Hemophilia: Roctavian offers a groundbreaking approach to treating severe Hemophilia A, a genetic disorder characterized by the deficiency of clotting factor VIII. Using an adeno-associated virus vector, Roctavian delivers a gene encoding a functional version of factor VIII to the patient’s liver cells. This gene therapy aims to boost the production of this crucial protein, reducing the need for frequent infusions of clotting factor concentrates. By potentially normalizing blood clotting and minimizing bleeding risks, Roctavian represents a major advancement in the treatment of Hemophilia A, moving towards a long-term or possibly permanent solution.
• Severe Combined Immunodeficiency (SCID): ADA-SCID, a severe form of SCID, is characterized by a critical deficiency in adenosine deaminase (ADA), an enzyme essential for immune function. Gene therapy for ADA-SCID involves inserting a functional copy of the ADA gene into the patient’s own stem cells, which are then reintroduced into the body. This therapy aims to restore immune system function, offering a viable alternative to lifelong enzyme replacement therapy and frequent immunoglobulin infusions. The successful restoration of immune function in these patients represents a significant breakthrough in the management of SCID, moving from supportive care to potential cures.
• Giant Axonal Neuropathy (GAN): GAN is a rare genetic disorder leading to progressive nerve degeneration. Gene therapies for GAN involve delivering functional copies of the defective gene directly into the cerebrospinal fluid. This method aims to provide a continuous supply of the missing protein necessary for nerve function. The goal is to slow or halt the progression of the disease, preserving motor functions and improving the patient’s quality of life. Although still experimental, these therapies offer a promising approach to managing and potentially mitigating the effects of this devastating condition.
• Leber Congenital Amaurosis (LCA): LCA is a hereditary retinal degenerative disorder that leads to blindness. Gene therapies for LCA focus on replacing or repairing the defective genes responsible for the condition. By introducing functional copies of these genes into retinal cells, these therapies aim to restore vision or significantly improve visual function. The success of these gene therapies represents a major milestone in the treatment of inherited forms of blindness, offering new possibilities for vision restoration where traditional treatments have been limited.
• Cancer Treatments: CAR T-cell therapies have revolutionized the treatment of certain blood cancers, such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). This approach involves genetically modifying a patient’s T cells to express chimeric antigen receptors (CARs) that target cancer cells. Once infused back into the patient, these engineered T cells seek out and destroy cancer cells with high specificity. The effectiveness of CAR T-cell therapies in achieving remission in cases resistant to traditional treatments highlights their potential as a powerful tool in oncology.
• Pompe Disease: Gene therapy for Pompe disease focuses on delivering a functional copy of the gene responsible for producing the enzyme alpha-glucosidase. This enzyme is essential for breaking down glycogen in muscle cells. Current research and clinical trials are investigating whether a single-dose gene therapy can replace the need for lifelong enzyme replacement therapy, offering a potential one-time treatment that could significantly improve muscle strength and respiratory function.
• Beta Thalassemia: Beta thalassemia is caused by mutations in the beta-globin gene, leading to ineffective hemoglobin production. Gene therapies for beta thalassemia aim to correct these mutations or introduce a functional beta-globin gene into hematopoietic stem cells. This approach reduces the need for regular blood transfusions and offers the possibility of a more durable and less invasive treatment solution. By addressing the underlying genetic defect, these therapies promise to improve patient outcomes and quality of life significantly.

Conclusion

The gene therapy market is poised for substantial growth, driven by significant advancements in technology, regulatory support, and increasing investment in research and development. With the FDA’s approval of multiple gene therapies for conditions like sickle cell disease, Duchenne muscular dystrophy, and metachromatic leukodystrophy, the potential for these therapies to treat previously untreatable diseases is being realized. Public and private funding, along with strategic collaborations, further accelerate the development and accessibility of these therapies. The continuous innovation and commitment to overcoming genetic disorders underline the transformative impact of gene therapy on modern medicine and patient care.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF